AstraZeneca Plc

AstraZeneca Plc

Sector: Pharmaceutical Preparations Region: United Kingdom

: | OTC Markets: AZNCF | NASDAQ OMX Stockholm: AZN | London Stock Exchange: AZN

AstraZeneca Plc is a global research-based biopharmaceutical company, which discovers, develops and markets medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious diseases. The firm sells products under the brands Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. The company was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

AstraZeneca's move to the Cambridge Biomedical Campus

An introduction to AstraZeneca's new UK R&D Centre and Global Corporate Headquarters, which will be part of the Cambridge Biomedical Campus, to the south of the city. AstraZeneca's Dr. Briggs Morrison, EVP Global Medicines Development & Chief Medical Officer, Dr. Mene Pangalos, EVP Innovative Medicines & Early Development and Dr. Bahija Jallal, EVP, Head of MedImmune comment on the significance of the move. External stakeholder viewpoints from Dr. Keith McNeil, Chief Executive, Cambridge University Hospitals, NHS Foundation Trust; Rt Hon Andrew Lansley, CBE, MP, Leader of the House of Commons and Member of Parliament, South Cambridgeshire, UK; Dr. Robert Winter, Managing Director, Eastern Academic Health Science Network, UK and Jeanette Walker, Project Director, Liberty Property Trust & Countryside Properties.

AstraZeneca Plc video

AstraZeneca's move to the Cambridge Biomedical Campus

News & Analysis